Market closed
Aardvark Therapeutics/$AARD
Aardvark Therapeutics shares are trading higher after the company reported its Q1 results.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aardvark Therapeutics
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Ticker
$AARD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
22
ISIN
US0029421007
Website
AARD Metrics
BasicAdvanced
$197M
-
-$4.40
-
-
Price and volume
Market cap
$197M
52-week high
$13.94
52-week low
$4.88
Average daily volume
94K
Financial strength
Current ratio
25.862
Quick ratio
25.311
Long term debt to equity
0.223
Total debt to equity
0.482
Management effectiveness
Return on assets (TTM)
-15.91%
Return on equity (TTM)
-23.57%
Valuation
Price to book
0.8
Price to tangible book (TTM)
0.8
Growth
Earnings per share change (TTM)
83.62%
AARD News
AllArticlesVideos
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewsWire·2 days ago
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
GlobeNewsWire·1 week ago
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aardvark Therapeutics stock?
Aardvark Therapeutics (AARD) has a market cap of $197M as of May 17, 2025.
What is the P/E ratio for Aardvark Therapeutics stock?
The price to earnings (P/E) ratio for Aardvark Therapeutics (AARD) stock is 0 as of May 17, 2025.
Does Aardvark Therapeutics stock pay dividends?
No, Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Aardvark Therapeutics dividend payment date?
Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders.
What is the beta indicator for Aardvark Therapeutics?
Aardvark Therapeutics (AARD) does not currently have a Beta indicator.